SCIB1 is a genetically-engineered cancer vaccine being developed by Scancell Holdings Plc as a treatment for melanoma.Scancell's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials.SCIB1 is a plasmid DNA which encodes a human antibody molecule engineered to express two cytotoxic T cell epitopes derived from the melanoma antigens Tyrosinase-Related Protein 2 (TRP2) and gp100 plus two helper T cell epitopes. Following immunisation, the engineered antibody is expressed and taken up by dendritic cells, resulting in the development of immune responses against tumour cells expressing the TRP2 and gp100 antigens. The major advantage of the Immunobody® technology is that the Fc component of the engineered antibody will be recognised by